How has Ginkgo Bioworks's deferred revenue, net of current portion changed year-over-year?

Ginkgo Bioworks's deferred revenue, net of current portion decreased by 3.1% year-over-year, from $80.38M to $77.9M.

What is the long-term trend for Ginkgo Bioworks's deferred revenue, net of current portion?

Over 3 years (2022 to 2025), Ginkgo Bioworks's deferred revenue, net of current portion has grown at a -24.5% compound annual growth rate (CAGR), from $174.77M to $75.18M.

Ginkgo Bioworks DNA Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

Thermo Fisher ScientificTMO

——

Charles River LaboratoriesCRL

——

RegenxbioRGNX

——

ClearPoint NeuroCLPT

——

Guardant HealthGH

——

Other financials

Income statement

See full

Revenue$19.5M-49.1%

Gross profit$16.4M-52.0%

Operating income-$71.4M+11.9%

Net income-$82.6M+9.2%

EPS (diluted)-$1.42+27.6%

Balance sheet

See full

Cash & equivalents$188.7M-46.9%

Total debt$410.7M-5.5%

Total equity$443.2M-31.6%

Total assets$1.0B-20.1%

Cash flow

See full

Operating cash flow-$46.7M+9.4%

CapEx$1.9M-74.6%

Free cash flow-$48.6M+17.8%

Valuation

See full

Market cap$625.16M+24.6%

Enterprise value$847.19M+45.9%

P/S4.4×+2.2×

Profitability

See full

Operating margin-210.7%+7.6pp

Net margin-215.4%+8.3pp

FCF margin-119%-21.2pp

Returns & leverage

See full

Return on equity-55.8%-1.8pp

Debt / equity0.9×+0.3×

Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ginkgo Bioworks's deferred revenue, net of current portion?: Ginkgo Bioworks (DNA) reported deferred revenue, net of current portion of $77.9M in Q1 2026.
How has Ginkgo Bioworks's deferred revenue, net of current portion changed year-over-year?: Ginkgo Bioworks's deferred revenue, net of current portion decreased by 3.1% year-over-year, from $80.38M to $77.9M.
What is the long-term trend for Ginkgo Bioworks's deferred revenue, net of current portion?: Over 3 years (2022 to 2025), Ginkgo Bioworks's deferred revenue, net of current portion has grown at a -24.5% compound annual growth rate (CAGR), from $174.77M to $75.18M.